KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$117.00
+1.36%Price chart
Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−31.2x
Market Cap
$9.73B
MomentumView details →
1D Return
+1.36%
YTD Return
+51.40%
RSI (14)
52.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−31.2x
Market Cap
$9.73B
RSI (14)
52.6
MomentumView details →
1D Return
+1.36%
YTD Return
+51.40%
SummaryUpdated Jun 1, 2026
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company founded in 2015 and headquartered in Watertown, Massachusetts. The company went public in August 2020 and has emerged as a pioneer in the field of targeted protein degradation, a novel therapeutic approach that harnesses the body's natural cellular machinery to eliminate disease-causing proteins. Since its inception, Kymera has built a robust pipeline of small molecule protein degraders targeting both oncology and immunology indications, with multiple programs advancing through clinical trials and a strategic partnership with Sanofi for its lead IRAK4 program.
Similar companies
Latest newsMore news →
Kymera Therapeutics announced presentations on KT-621, a first-in-class oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses.10d agoKymera Therapeutics completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule.36d agoKymera Therapeutics reported Q2 2026 financial results with collaboration revenue of $65.0 million, a net loss of $61.2 million, and diluted EPS of -$0.62.37d ago